RPL29

PF3D7_1460300 (RPL29) is a structural component of the 60S large subunit of the Plasmodium falciparum cytoplasmic 80S ribosome, resolved as part of the assembled complex by high-resolution cryo-EM (PMID:24913268, PMID:26432834). Its position within the 60S subunit has been confirmed across multiple independent structural datasets, including ribosomes purified from blood-stage schizonts, drug-bound complexes, and native translating ribosomes imaged in situ inside infected erythrocytes (PMID:26432834, PMID:28288098, PMID:40825879). These structures place RPL29 within a ribosome that displays features distinguishing it from the mammalian ribosome and that serves as a target for Plasmodium-directed translation inhibitors (PMID:26432834, PMID:28288098, PMID:40825879). No experiment in the available corpus interrogates a function, binding partner, or activity specific to RPL29 beyond its membership in the 60S subunit; its role is inferred solely from being resolved as part of the ribosomal complex.

1. 2014 Medium

   The first question was whether RPL29 is a bona fide constituent of the P. falciparum ribosome; solving the intact 80S structure placed it within the assembled 60S subunit.

   Evidence Cryo-EM structure of the P. falciparum 80S ribosome at 3.2 Å resolution

   PMID:24913268

   Open questions at the time

   • No functional experiment specific to RPL29; role inferred only from complex membership
   • No defined interaction network or activity for the protein itself
   • Contribution of RPL29 to subunit assembly or translation not tested
2. 2015 Medium

   Building atomic models from schizont-derived ribosomes confirmed RPL29 placement in the 60S subunit and situated it within a ribosome architecture distinct from the mammalian counterpart.

   Evidence Cryo-EM with flexible fitting and atomic model building from purified schizont ribosomes

   PMID:26432834

   Open questions at the time

   • Structural presence does not establish any RPL29-specific function
   • Species-distinguishing features attributed to the whole ribosome, not to RPL29 specifically
3. 2017 Medium

   Whether the ribosome carrying RPL29 is a viable antimalarial drug target was addressed by resolving a mefloquine-bound 80S structure, again with RPL29 as a confirmed 60S component.

   Evidence Cryo-EM at 3.2 Å with mefloquine bound and mutagenesis of binding residues

   PMID:28288098

   Open questions at the time

   • Drug binding and mutagenesis concern other ribosomal sites, not RPL29
   • No evidence RPL29 participates in drug binding
4. 2025 Medium

   Whether RPL29 is part of natively translating ribosomes in the cellular context was established by in situ cryo-ET, which also captured drug-induced shifts in elongation states of the ribosome.

   Evidence In situ cryo-electron tomography inside infected erythrocytes with translation inhibitor perturbation

   PMID:40825879

   Open questions at the time

   • Perturbation effects are attributed to the ribosome/elongation factors, not to RPL29
   • No RPL29-specific role in translation elongation demonstrated

• No function, binding partner, or activity specific to RPL29 has been defined beyond its structural membership in the 60S subunit.
• No genetic knockdown/knockout phenotype for RPL29 characterized
• No RPL29-specific interactions or post-translational regulation reported
• Any specialized or extraribosomal function remains untested